Nanoparticle Technology for Respiratory Tract Mucosal Vaccine Delivery

Johnson, Lewis D.; Mecham, Jeffrey B.; Quinn, Frederick D.; Hickey, Anthony

doi:10.14356/kona.2020013

Cited by 5 publications

(5 citation statements)

References 144 publications

(139 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the future, pulmonary administration as a route of TB treatment application should be explored. It may be possible to adopt an NP strategy to delivery mycobacterial antigens to the lung mucosa and protect against disease [42]. In murine models, the M. tuberculosis heparin-binding haemagglutinin antigen has been adsorbed in wax particles and has been shown to provide immunization [42].…”

Section: Discussionmentioning

confidence: 99%

“…It may be possible to adopt an NP strategy to delivery mycobacterial antigens to the lung mucosa and protect against disease [42]. In murine models, the M. tuberculosis heparin-binding haemagglutinin antigen has been adsorbed in wax particles and has been shown to provide immunization [42]. Delivery of particles of this nature to the lungs may be a means of inducing an enhanced innate immune response [42].…”

Section: Discussionmentioning

confidence: 99%

“…In murine models, the M. tuberculosis heparin-binding haemagglutinin antigen has been adsorbed in wax particles and has been shown to provide immunization [42]. Delivery of particles of this nature to the lungs may be a means of inducing an enhanced innate immune response [42]. Such an approach may prove a worthy pursuit in future human trials.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Tuberculosis Vaccines: An Update of Recent and Ongoing Clinical Trials

2021

View full text Add to dashboard Cite

TB remains a global health challenge and, until now, only one licensed vaccine (the BCG vaccine) is available. The main goal of this work is to assess the progress in the development of new TB vaccines and highlight the research in nanovaccines. A review was conducted using a methodology with the appropriate keywords and inclusion and exclusion criteria. The search revealed 37 clinical trials that were further reviewed. The results available have reported good immunogenicity and safety profiles for the vaccines under investigation. Over the last five years, the vaccines, VPM1002 and Vaccae, have moved ahead to phase III clinical trials, with the remaining candidate vaccines progressing in phase I and II clinical trials. RUTI and ID93+GLA-SE involve the use of nanoparticles. This strategy seems promising to improve the delivery, efficacy, cost, and storage conditions of the existing TB vaccines. In conclusion, the use of nanovaccines may be an option for both prevention and treatment. However, further studies are necessary for the development of novel TB vaccines.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Tuberculosis Vaccines: An Update of Recent and Ongoing Clinical Trials

2021

View full text Add to dashboard Cite

show abstract

“…Research into the inclusion of nanostructures in spraydried solid powders has grown in the last couple of decades (Johnson et al, 2020;Malamatari et al, 2020). This kind of formulation is possible through the preparation of a feed nanoemulsion or nanosuspension by dispersing liposomes (Maniyar and Kokare, 2019), nanodroplets (Gomez et al, 2019), nanoparticles (Tsapis et al, 2002;, and other forms of immiscible nanostructures (Malamatari et al, 2020;Saallah and Lenggoro, 2018;Wang Z. et al, 2022).…”

Section: Nanostructuresmentioning

confidence: 99%

Mechanistic Formulation Design of Spray-Dried Powders

Ordoubadi

Wang

Vehring

2023

KONA

View full text Add to dashboard Cite

Spray drying is gaining traction in the pharmaceutical industry as one of the processing methods of choice for the manufacture of solid dosage forms intended for pulmonary, oral, and parenteral delivery. This process is particularly advantageous because of its ability to produce engineered particles with improved efficacy and stability by combining active pharmaceutical ingredients or biologics with appropriate excipients. Moreover, due to its high throughput, continuous operation, and ability to produce thermostable solid powders, spray drying can be a manufacturing method of choice in the production of drugs and other formulations, including vaccines, for global distribution. Formulation design based on a mechanistic understanding of the different phenomena that occur during the spray drying of powders is complicated and can therefore make the use of available particle formation models difficult for the practitioner. This review aims to provide step-by-step guidance accompanied by critical background information for the successful formulation design of spray-dried microparticles. These include discussion of the tools needed to estimate the surface concentration of each solute during droplet drying, their times and modes of solidification, and the amount of glass stabilizers and shell formers required to produce stable and dispersible powders.

show abstract

“…Inhalation systems can be a useful drug delivery method for both topical and systemic administration of drugs. Several types of research have been conducted on such administration systems, because particle design including nanoparticle engineering and characterization is important to achieve the most efficient drug delivery (Johnson et al, 2020;Price et al, 2019). Kawashima et al have also tried to prepare suitable drug crystals and their formulations for dry powder inhalation systems (Kawashima et al, 1998a;1998b).…”

Section: Transpulmonary Administration Of Liposomal Drugsmentioning

confidence: 99%

Contribution of Particle Design Research to the Development of Patient-Centric Dosage Forms

Takeuchi

2022

KONA

View full text Add to dashboard Cite

A variety of dosage forms have been developed in order to achieve effective and safe drug delivery in topical or systemic drug administrations. In this review, formulation research and process issues related to a popular oral dosage form, the tablet, are introduced. Research on oral dosage forms, including orally disintegrating tablets (ODTs) and films (ODFs), which have recently been developed with an aim toward more patient-centric drug therapy, is also introduced. Another trend in recent drug therapy is an increase in the number of large bioactive molecules among the newly developed active pharmaceutical ingredients (APIs). To design dosage forms for these APIs, novel dosage form design and administration routes are required. For this purpose, we have tried to effectively use the polymer-coated liposomes in oral, pulmonary and ophthalmic administration. For example, suitable polymers were introduced for the design of specific administration routes, such as mucoadhesive liposomes for oral administration. The key point in these researches is the particle design for the component particles of final dosage forms, both in the case of coarse powder particle design for formulating solid dosage forms and in the case of colloidal particle design, such as the design of liposomes for peptide drug delivery.

show abstract

Nanoparticle Technology for Respiratory Tract Mucosal Vaccine Delivery

Cited by 5 publications

References 144 publications

Tuberculosis Vaccines: An Update of Recent and Ongoing Clinical Trials

Tuberculosis Vaccines: An Update of Recent and Ongoing Clinical Trials

Mechanistic Formulation Design of Spray-Dried Powders

Contribution of Particle Design Research to the Development of Patient-Centric Dosage Forms

Contact Info

Product

Resources

About